Article
Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group.
The pharmacogenomics journal - 1 Jan 2018
Floyd J S, Sitlani C M, Avery C L, Noordam R, Li X, Smith A V, Gogarten S M, Li J, Broer L, Evans D S, Trompet S, Brody J A, Stewart J D, Eicher J D, Seyerle A A, Roach J, Lange L A, Lin H J, Kors J A, Harris T B, Li-Gao R, Sattar N, Cummings S R, Wiggins K L, Napier M D, Stürmer T, Bis J C, Kerr K F, Uitterlinden A G, Taylor K D, Stott D J, de Mutsert R, Launer L J, Busch E L, Méndez-Giráldez R, Sotoodehnia N, Soliman E Z, Li Y, Duan Q, Rosendaal F R, Slagboom P E, Wilhelmsen K C, Reiner A P, Chen Y-Di, Heckbert S R, Kaplan R C, Rice K M, Jukema J W, Johnson A D, Liu Y, Mook-Kanamori D O, Gudnason V, Wilson J G, Rotter J I, Laurie C C, Psaty B M, Whitsel E A, Cupples L A, Stricker B H
Abstract excerpt
Sulfonylureas, a commonly used class of medication used to treat type 2 diabetes, have been associated with an increased risk of cardiovascular disease. Their effects on QT interval duration and related electrocardiographic phenotypes are potential mechanisms for this adverse effect. In 11 ethnically diverse cohorts that included 71 857 European, African-American and Hispanic/Latino ancestry individuals with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
